ArticleHIV medicine2026
History of sexually transmitted infections among mpox cases in the 2022 outbreak in Spain.
Article in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveThe aim was to describe the history of sexually transmitted infections (STIs) among adult mpox men cases and to analyse sociodemographic and epidemiological characteristics according to the presence or absence of any STI diagnosed 1 or 6 months previous to mpox diagnosis during the 2022 outbreak in Spain.
methodsA cross-sectional study was conducted as part of a multicentre study in seven Spanish regions. Mpox patients were enrolled by the epidemiological surveillance services from June 2022 to January 2023. We conducted descriptive and bivariate analyses to compare sociodemographic, epidemiological and clinical characteristics of mpox according to the presence of a previous STI diagnosis. Associations were assessed using logistic regression to estimate crude odds ratio (OR) and adjusted odds ratio (aOR) with 95% confidence intervals (95% CI).
resultsA total of 1202 mpox individuals were included (96.4% were men); 36% (417/1159) of males had previous STI during the 6 months previous to mpox diagnosis. Chemsex practice (aOR 1.66, 95% CI: 1.11-2.47), practicing sex in leisure places (aOR 1.68, 95% CI: 1.12-2.51), having HIV diagnosis (aOR 1.91, 95% CI: 1.32-2.77) and using pre-exposure prophylaxis (PrEP) (aOR 4.43, 95% CI: 3.05-6.45) were more frequent among males with a history of STI in the 6 months previous to mpox diagnosis. No statistical differences were found in mpox clinical manifestations and hospitalization according to STI history.
conclusionsOverlapping risk behaviours and shared transmission routes contributed to the high prevalence of STI history in mpox cases. Epidemiological characteristics studied in mpox cases with previous STI may help identify target populations and planning an integrated prevention strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.